[go: up one dir, main page]

WO2005028619A3 - Nanoliter-scale synthesis of arrayed biomaterials and screening thereof - Google Patents

Nanoliter-scale synthesis of arrayed biomaterials and screening thereof Download PDF

Info

Publication number
WO2005028619A3
WO2005028619A3 PCT/US2004/030095 US2004030095W WO2005028619A3 WO 2005028619 A3 WO2005028619 A3 WO 2005028619A3 US 2004030095 W US2004030095 W US 2004030095W WO 2005028619 A3 WO2005028619 A3 WO 2005028619A3
Authority
WO
WIPO (PCT)
Prior art keywords
screening
substrate
nanoliter
polymer
scale synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/030095
Other languages
French (fr)
Other versions
WO2005028619A2 (en
Inventor
Daniel G Anderson
Shulamit Levenberg
Robert S Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/843,707 external-priority patent/US20050019747A1/en
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to EP04788758A priority Critical patent/EP1675943A4/en
Priority to CA002539670A priority patent/CA2539670A1/en
Publication of WO2005028619A2 publication Critical patent/WO2005028619A2/en
Publication of WO2005028619A3 publication Critical patent/WO2005028619A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A population of embryonic epithelial cells produced in vitro from embryonic stem cells. In one embodiment, at least 45% of the cells express cytokeratin, for example, cytokeratin-7. A method of screening cell-polymer interactions. The method includes depositing monomers as a plurality of discrete elements on a substrate, causing the deposited monomers to polymerize, thereby creating an array of discrete polymer elements on the substrate, incubating the substrate in a cell-containing culture medium, and characterizing a predetermined cell behavior on each polymer element.
PCT/US2004/030095 2003-09-15 2004-09-15 Nanoliter-scale synthesis of arrayed biomaterials and screening thereof Ceased WO2005028619A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04788758A EP1675943A4 (en) 2003-09-15 2004-09-15 NANOLITRE SYNTHESIS OF BIOMATERIALS IN NETWORKS AND SCREENING THEREOF
CA002539670A CA2539670A1 (en) 2003-09-15 2004-09-15 Nanoliter-scale synthesis of arrayed biomaterials and screening thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US50316503P 2003-09-15 2003-09-15
US60/503,165 2003-09-15
US57018704P 2004-05-12 2004-05-12
US10/843,707 US20050019747A1 (en) 2002-08-07 2004-05-12 Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US10/843,707 2004-05-12
US60/570,187 2004-05-12

Publications (2)

Publication Number Publication Date
WO2005028619A2 WO2005028619A2 (en) 2005-03-31
WO2005028619A3 true WO2005028619A3 (en) 2005-09-09

Family

ID=34381975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030095 Ceased WO2005028619A2 (en) 2003-09-15 2004-09-15 Nanoliter-scale synthesis of arrayed biomaterials and screening thereof

Country Status (3)

Country Link
EP (1) EP1675943A4 (en)
CA (1) CA2539670A1 (en)
WO (1) WO2005028619A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006487B2 (en) 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
WO2007140595A1 (en) * 2006-06-06 2007-12-13 Societe De Commercialisation Des Produits De La Recherche Appliquee - Socpra-Sciences Et Genie S.E.C. Assay supports comprising a peg support, said support attached from a peg solution in cloud point (theta solvent) conditions
WO2009099539A2 (en) * 2008-01-30 2009-08-13 Corning Incorporated (meth)acrylate surfaces for cell culture, methods of making and using the surfaces
WO2009099555A2 (en) 2008-01-30 2009-08-13 Corning Incorporated Synthetic surfaces for culturing cells in chemically defined media
KR101635750B1 (en) * 2008-01-30 2016-07-04 아스테리아스 바이오세라퓨틱스, 인크. Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
US8241907B2 (en) * 2008-01-30 2012-08-14 Geron Corporation Synthetic surfaces for culturing stem cell derived cardiomyocytes
US8329469B2 (en) * 2008-01-30 2012-12-11 Geron Corporation Swellable (meth)acrylate surfaces for culturing cells in chemically defined media
KR101734955B1 (en) 2008-11-07 2017-05-12 메사추세츠 인스티튜트 오브 테크놀로지 Aminoalcohol lipidoids and uses thereof
WO2011014845A1 (en) * 2009-07-31 2011-02-03 Nanoink, Inc. Screening system to identify patterns on substrate surfaces for inducing stem cell differentiation and producing homogenous population of a desired cell type
NZ600616A (en) 2009-12-01 2014-11-28 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP2691443B1 (en) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Conjugated lipomers and uses thereof
HK1199206A1 (en) 2011-06-08 2015-06-26 夏尔人类遗传性治疗公司 Lipid nanoparticle compositions and methods for mrna delivery
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nuclease resistant polynucleotides and uses thereof
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
JP6586075B2 (en) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド Method for purifying messenger RNA
HRP20181580T1 (en) 2013-03-14 2019-02-22 Translate Bio, Inc. CFTR IRNK PREPARATIONS AND RELATED PROCEDURES AND USES
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
ES2707966T3 (en) 2013-10-22 2019-04-08 Translate Bio Inc MRNA therapy for the deficiency in argininosuccinate synthesis
SG11201602943PA (en) 2013-10-22 2016-05-30 Shire Human Genetic Therapies Lipid formulations for delivery of messenger rna
MX2016005239A (en) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Mrna therapy for phenylketonuria.
EP3636742B1 (en) 2014-04-25 2025-11-05 Translate Bio, Inc. Methods for purification of messenger rna
JP6557722B2 (en) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Biodegradable lipids for delivery of nucleic acids
UA121863C2 (en) 2014-06-24 2020-08-10 Транслейт Байо, Інк. Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
GB201416078D0 (en) * 2014-09-11 2014-10-29 Univ Nottingham Cell culture substrate
EP3585417B1 (en) 2017-02-27 2023-02-22 Translate Bio, Inc. Method of making a codon-optimized cftr mrna
ES2993135T3 (en) 2017-05-16 2024-12-23 Translate Bio Inc Codon-optimized mrna encoding cftr for use in treating cystic fibrosis
CN118421617A (en) 2018-08-24 2024-08-02 川斯勒佰尔公司 Method for purifying messenger RNA
CA3120647A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825370A1 (en) * 2001-05-31 2002-12-06 Inst Nat Sante Rech Med KERATINOCYTES OBTAINED FROM MAMMALIAN EMBRYONIC STEM CELLS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI Y. ET AL: "Plasticity of the urothelial phenotype: effects of gastro-intestinal mesenchyme/stroma and implications for urinary tract reconstruction", DIFFERENTIATION, vol. 66, 2000, pages 126 - 135, XP002989066 *
See also references of EP1675943A4 *

Also Published As

Publication number Publication date
WO2005028619A2 (en) 2005-03-31
EP1675943A2 (en) 2006-07-05
EP1675943A4 (en) 2007-12-05
CA2539670A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
WO2005028619A3 (en) Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
Mei et al. Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells
Villa-Diaz et al. Concise review: the evolution of human pluripotent stem cell culture: from feeder cells to synthetic coatings
Charnley et al. Integration column: microwell arrays for mammalian cell culture
Moeller et al. A microwell array system for stem cell culture
Delalat et al. Microengineered bioartificial liver chip for drug toxicity screening
Cimetta et al. Production of arrays of cardiac and skeletal muscle myofibers by micropatterning techniques on a soft substrate
GB0312481D0 (en) Antibodies
WO2002026941A3 (en) Primitive neural stem cells and method for differentiation of stem cells to neural cells
WO2002097068A3 (en) Keratinocytes obtained from embryonic stem cells of mammals
WO2012034101A3 (en) Expandable cell source of neuronal stem cell populations and methods for obtaining and using them
Wang et al. Micromolded arrays for separation of adherent cells
EP2245453A4 (en) CELL CULTURE NETWORK SYSTEM FOR AUTOMATED TESTING AND METHODS OF OPERATION AND MANUFACTURE THEREOF
WO2001081549A3 (en) Hepatocyte lineage cells derived from pluripotent stem cells
Tronser et al. Miniaturized platform for high-throughput screening of stem cells
Sun et al. UV-modulated substrate rigidity for multiscale study of mechanoresponsive cellular behaviors
Zonca Jr et al. High‐throughput screening of substrate chemistry for embryonic stem cell attachment, expansion, and maintaining pluripotency
WO2009102697A3 (en) Methods of obtaining antigen-specific t cell populations
Leclerc et al. Guidance of liver and kidney organotypic cultures inside rectangular silicone microchannels
KR101961459B1 (en) Device and method for single cell screening based on inter-cellular communication
Marel et al. Arraying Cell Cultures Using PEG‐DMA Micromolding in Standard Culture Dishes
Wilson et al. 3D Microwell platforms for control of single cell 3D geometry and intracellular organization
KR102075035B1 (en) Method for preparing pellet of chondrocytes using nano-pattern sheet and 3D cell co-culturing plate for differentiation
JP7630836B2 (en) Isolation of live cells following high-throughput long-term time-lapse microscopy
ATE469209T1 (en) PRODUCTION AND USE OF BASAL MEMBRANE PARTICLES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2539670

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004788758

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004788758

Country of ref document: EP